Anticancer Effects of 15d-Prostaglandin-J2 in Wild-Type and Doxorubicin-Resistant Ovarian Cancer Cells: Novel Actions on SIRT1 and HDAC
2011

Effects of 15d-Prostaglandin-J2 on Ovarian Cancer Cells

publication 10 minutes Evidence: moderate

Author Information

Author(s): de Jong Edwin, Winkel Peter, Poelstra Klaas, Prakash Jai, Gires Olivier

Primary Institution: University of Groningen, Groningen, The Netherlands

Hypothesis

Can 15d-Prostaglandin-J2 induce apoptosis in doxorubicin-resistant ovarian cancer cells?

Conclusion

15d-Prostaglandin-J2 has a high therapeutic potential to kill drug-resistant tumor cells and inhibits key pathways involved in drug resistance.

Supporting Evidence

  • 15d-PGJ2 induced apoptosis in both wild-type and doxorubicin-resistant ovarian cancer cells.
  • Treatment with 15d-PGJ2 reduced the expression of drug resistance genes like MDR1 and SIRT1.
  • 15d-PGJ2 inhibited cell migration and transformed cell morphology.
  • The effects of 15d-PGJ2 were mediated through NF-κB and not through PPARγ pathways.

Takeaway

This study shows that a natural compound can help kill cancer cells that are usually resistant to treatment, making it a potential new medicine for tough cancers.

Methodology

The study involved cell viability assays, caspase activity assays, gene expression studies, and wound healing assays using ovarian cancer cell lines.

Limitations

The study primarily focuses on in vitro experiments, which may not fully replicate in vivo conditions.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1371/journal.pone.0025192

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication